Maha Hussain

Oct 28, 2024 | cancernetwork.com | Maha Hussain

Prostate cancer remains the most common tumor type in males and the second leading cause of cancer deaths overall in the United States.1 With an estimated 299,010 new cases expected in 2024, the average lifetime risk of diagnosis is about 17%, while the risk of dying from the disease is approximately 3%. The landscape of prostate cancer management has been dramatically reshaped by precision medicine.

May 9, 2024 | jamanetwork.com | Maha Hussain |Institut Gustave Roussy |Neal Shore

Abstract Importance  Metastatic hormone-sensitive prostate cancer is currently an incurable disease. Despite a high response rate to androgen-deprivation therapy, most cases progress to castration-resistant disease, the terminal phase. This review provides a summary of the most recent evidence for current and emerging management strategies, including treatment intensification with combinations of therapies.

Apr 22, 2024 | europeanurology.com | Fred Saad |E. David Crawford |Luke T Nordquist |Maha Hussain |Bertrand Tombal |Karim Fizazi | +10 more

AbstractAddition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and their association with outcomes. ARASENS is an international, double-blind, phase 3 study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to darolutamide 600 mg orally twice daily (n = 651) or placebo (n = 654), both with ADT + docetaxel.

Apr 8, 2024 | cancernetwork.com | Maha Hussain |Sarah Fenton

As part of Breaking Barriers: Women in Oncology, Maha H. Hussain, MD, and Sarah E. Fenton, MD, PhD, spoke with CancerNetwork® about developments in their careers and the evolution of research in the genitourinary oncology (GU) field. Additionally, they discussed their personal experiences in the field, which ranged from applying key pieces of advice from former mentors, handling challenges, and maintaining a healthy work/life balance. Hussain is a Genevieve E.

Apr 3, 2024 | cancernetwork.com | Maha Hussain |Sarah Fenton

Work-life balance can be especially difficult for female physicians in genitourinary (GU) oncology, given the demanding nature of the field. In a recent conversation with CancerNetwork® in Breaking Barriers: Women in Oncology, Maha H. Hussain, MD, and Sarah E. Fenton, MD, PhD, focused on how they decided to start families and if it impacted their work. Hussain, a Genevieve E.